Prognostic implications of overt congestion in heart failure with preserved ejection fraction and the interaction with spironolactone: Insights from TOPCAT-Reference-Cited by-同舟云学术

Prognostic implications of overt congestion in heart failure with preserved ejection fraction and the interaction with spironolactone: Insights from TOPCAT

Published:2023-10-10 Issue: Volume: Page:
ISSN:0366-6999
Container-title:Chinese Medical Journal
language:en
Short-container-title:

Author:

Lin Yingwen¹,Zhao Hengli²,Hu Dongtu¹,Huang Jia³,Peng You⁴,Li Juncong¹,Xu Dingli¹,Zeng Qingchun¹

Affiliation:

1. State Key Laboratory of Organ Failure Research, Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, China

2. Guangdong Provincial Key Laboratory of Clinical Pharmacology, Medical Research Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong 510515, China

3. Department of Radiology, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510150, China

4. Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, China.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine,General Medicine

Reference4 articles.

1. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction;Solomon;Eur Heart J,2016

2. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: A randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction;Desai;Am Heart J,2011

3. Utility of the cardiovascular physical examination and impact of spironolactone in heart failure with preserved ejection fraction;Selvaraj;Circ Heart Fail,2019

4. Mineralocorticoid receptor antagonists in patients with heart failure: Current experience and future perspectives;Pitt;Eur Heart J Cardiovasc Pharmacother,2017